Podcasts about circulating

Pass the shuriken on the left hand side, it's Circulating the Tapes, the MST3K Watchalong podcast on The AewchCast. In this episode, Aewch needs a skinnier stunt double as he reviews Master Ninja 1.Watch Master Ninja 1 Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepThe Crawling EyeSocial Media: @JustAewchEmail: aewch64@gmail.com

Love the episode? Send us a text!In this special episode of Breast Cancer Conversations, host Laura Carfang speaks with Dr. Troso  about the evolving role of DNA testing in breast cancer care. Together, they break down the three main types of testing:Hereditary genetic testing: Identifying inherited mutations such as BRCA1, BRCA2, and PALB2 (among others) that increase cancer risk and influence prevention and treatment decisions.Somatic (tumor) testing: Analyzing mutations within the tumor itself—such as PIK3CA or ESR1 mutations—to guide targeted therapies and manage resistance in advanced disease.Circulating tumor DNA (ctDNA) testing: Also known as a liquid biopsy, this emerging tool uses blood tests to detect cancer DNA fragments. It holds promise for monitoring recurrence, guiding treatment earlier, and advancing clinical trials.Tune into this Special! 

How can conversation become a real driver of circular transformation? In this episode, George Marshall explains why conversations are central to circular change and how to design them to build trust, reach across difference, and motivate action. Circular economy strategies often focus on systems and structures but lasting change only happens when people connect new behaviors to their own identity and values. Without shared understanding and engagement, technical solutions risk staying at the surface. Recorded live at the LOOP Forum 2025, his keynote explores how businesses can move beyond top-down messaging to create real dialogue that activates people at every level of an organisation. This episode is part of our series on the LOOP Forum 2025 highlights, bringing you the key ideas and insights from this year's leading Nordic event on circularity.

Get born to be mild, because it's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this episode, Aewch tosses around more smack than Maxwell's silver hammer as he reviews The Hellcats.Watch The Hellcats Right Here!The CTT UERL Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmThe Million Eyes of SumuruLords of the DeepThe Crawling EyeSocial Media: @JustAewchEmail: aewch64@gmail.com

All bikini but no A-go-go, it's Circulating the Tapes, the MST3K watchalong podcast on The AewchCast. On this episode, what Aewch wouldn't give to work for a cabal of sexy evil women, as he reviews The Million Eyes of Sumuru.Watch The Million Eyes of Sumuru Right Here!The CTT Ultimate Episode Ranking Top 10!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersSwamp DiamondsPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedSocial Media: @JustAewchEmail: aewch64@gmail.com

Don't Touch that Connors, it's Circulating the Tapes, the MST3K watchalong Podcast on The AewchCast. On this episode, Aewch goes red, white, and blonde, as he reviews Swamp Diamonds. Plus, the short that gave the A/V club hope, What to Do on a Date.Watch Swamp Diamonds Right Here!The CTT Top Ten!I Accuse My ParentsGodzilla vs MegalonAvalancheThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedTeenage CavemanSocial Media: @JustAewchEmail: aewch64@gmail.com

Put on your best polyester skisuit, it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch swears he can tell the difference between real snow and styrofoam boulders as he reviews Avalanche.Watch Avalanche…on your copy of the DVD.The CTT Ultimate Episode Ranking Top Ten List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedTeenage CavemanRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Follow the Rule and listen to Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch dares to enter the forbidden zone, as he reviews Teenage Caveman. Plus, TWO shorts, the nightmare of safety known as Aquatic Wizards, and the scourge to animals Catching Trouble.Watch Teenage Caveman Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmLords of the DeepThe Crawling EyeThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Get your hands on some spiritual Gak, because it's Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch borrows a mini-sub(Don't worry, there's plenty left), as he reviews Lords of the Deep.Watch Lords of the Deep…on your copy of the DVD.The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmThe Crawling EyeThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

BUFFALO, NY – July 24, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on July 23, 2025, titled “Extracorporeal blood filtration leading to tumor growth arrest and reduced analgesic requirements in Stage IV poorly differentiated pancreatic adenocarcinoma: A case report.” In this report, Susanna Ulahannan from the University of Oklahoma Health Sciences Center and colleagues describe the use of extracorporeal blood filtration in a patient with metastatic pancreatic cancer. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up. Metastatic pancreatic cancer is difficult to treat and is often diagnosed at an advanced stage. In this case, a 51-year-old woman with stage IV poorly differentiated adenocarcinoma chose not to undergo standard chemotherapy. Instead, she received extracorporeal blood filtration with the Seraph® 100 device, which is designed to remove circulating tumor cells (CTCs) from the bloodstream. CTCs are thought to contribute to the spread of cancer to other organs. “Circulating tumor cells (CTC's) are tumor cells that are shed from the primary tumor and travel via blood or lymphatic system to form micro metastases in distant organs under a suitable environment.“ The patient received between nine and twelve treatments over the course of a year. These treatments were performed both abroad, where the device is approved for this use, and under a clinical protocol in the United States. Medical imaging showed that her disease remained stable, with no new metastases detected. She also reported improvements in appetite, energy levels, and pain control. Her opioid use was reduced by 90%. Blood samples confirmed a drop in CTC levels after treatment. This observation supports the idea that removing CTCs might help limit cancer progression in some patients. However, given that this is a single case report, larger clinical studies are needed to evaluate the effectiveness of this approach. The mechanism behind the patient's pain relief is not fully understood. Authors suggest that it may be related to the reduction of tumor cells or inflammatory molecules in the blood. Researchers noted that pro-inflammatory cytokines, known to influence pain, could also have been affected by the filtration process. This is the first documented case of stable disease and reduced symptoms following CTC filtration in advanced pancreatic cancer. While these findings should not be generalized, they highlight an approach outside standard protocols that should be further explored in clinical research. Future studies will be needed to determine whether this method can contribute to symptom management or disease control in other patients with metastatic pancreatic cancer. DOI - https://doi.org/10.18632/oncotarget.28756 Correspondence to - Susanna Ulahannan - susanna-ulahannan@ouhsc.edu Video short - https://www.youtube.com/watch?v=dro6iUGDrVQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28756 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, extracorporeal blood filtration, circulating tumor cells, metastatic pancreatic cancer, seraph 100, OncoBind To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

I'm…getting a…vision…A Podcast called Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch does a deep dive into some Best Brains history, as he reviews the first episode of MST3K (Sans KTMA), The Crawling Eye. Watch The Crawling Eye Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsGodzilla vs MegalonThe StarfightersPrince of SpaceSquirmThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Jeff Grubb is joined by Kat Bailey to start the week. We chat about a banana boatload of Donkey Kong Bananza related stories, the price of the Asus ROG Ally Xbox device getting leaked, EA shelving the Need for Speed franchise, and more stories for your Monday morning!

Get your monster goofin' going, because this is Circulating the Tapes, the MST3K watchalong Podcast on The Aewchcast. On this episode, Aewch embodies the spirit of bad movies as he reviews Godzilla vs. Megalon.Watch Godzilla vs Megalon Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsThe StarfightersPrince of SpaceSquirmThe Day Time EndedRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

(SPOILER) Your Daily Roundup covers Big Brother 27 premiering tonight, the rumor mill already starting about one contestant, Jesse from the Valley on a podcast giving his thoughts on Janet, and a new raw dogging challenge on a flight that is more up my alley.       Music written by Jimmer Podrasky (B'Jingo Songs/Machia Music/Bug Music BMI) Ads: ZocDoc – Click on https://zocdoc.com/RealitySteve to find and instantly book a top rated doctor today.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Is that a Weird green Mayan pyramid in your pocket, or are you happy to see me? Because this is Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch tries to keep up, but falls off the edge of the universe, as he reviews The Day Time Ended.Watch The Day Time Ended….on your own copy of the dvd.The CTT Ultimate Episode Ranking List!I Accuse My ParentsThe StarfightersPrince of SpaceSquirmRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

You da worm face now! Because this is Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch wonders if you would listen to his podcast if it was a worm podcast, as he reviews Squirm. Plus, the bonus short, A Case of Spring Fever.Watch Squirm Right Here!The CTT Ultimate Episode Ranking List!I Accuse My ParentsThe StarfightersPrince of SpaceRacket GirlsSocial Media: @JustAewchEmail: aewch64@gmail.com

Your weapons have no effect on Circulating the Tapes, the MST3K watchalong podcast on The Aewchcast. On this episode, Aewch likes bootblacking very much, as he reviews Prince of Space.Watch Prince of Space Right Here!Or watch our next episode: Squirm!The Circulating the Tapes Ultimate Episode Ranking List:1: I Accuse My Parents2:The Starfighters3. Racket GirlsSocial Media: @JustAewch

Get your corn detassled, it's Circulating the Tapes, the MST3K Watchalong Podcast on The AewchCast. On this episode, Aewch attempts to find his need for speed, but gets a lot of jet refueling, as he reviews The Starfighters.Watch The Starfighters Right Here!Social Media: @JustAewchEmail: aewch64@gmail.comNext Episode: Prince of Space!

Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Get your essays ready for the contest, It's Circulating The Tapes, the Mystery Science Theater 3000 Watchalong Podcast on The AewchCast. On this episode, Aewch runs some packages and gets the carrots on ice, as he reviews I Accuse My Parents, with the short The Truck Farmer.Watch I Accuse My Parents Right Here!Listen to our episode on Racket Girls Right Here!Social Media: @JustAewch

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

"The biggest mistake is a mindset of scarcity—the fear that there's never enough. The solution is to begin circulating money. Even small acts matter." – Tom LeNoble

Look for the show notes at AnokaCountyHistory.org

Thank God It's Tuesday! We are having a zen day at Spa Mirbeau, hanging out from the Aqua Terrace after a glow facial and plenty of time bouncing from sauna to steam room to shower. We catch up on Intern Aaron's college-y weekend, the latest in documentary TV and play a good old game of Roast or Toast.The Buttonista Show is presented by Michelob Ultra

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in the Prognostic Value of Circulating Biomarkers in Patients Presenting With Acute Chest Pain

Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode of AmericanReef, we take a look at the Paletta 500 gallon reef tank 3 months after he replaced most all of the smaller circulating pumps with two larger ones.

There have been reported sightings of ICE agents across the North State on social media. But local organizations and law enforcement agencies report most are likely false alarms. Also, Chico State President Steve Perez sent a message to the campus community last week in response to worries about the school's fiscal situation amid a freeze on federal funding, and the second manual snow survey of the season measured 22 inches of snow depth, only 46 percent of average for the location near Echo Summit.

Do you know someone who is sick right now? There is a "Quademic" going around..  as referred to by health officials. 4 major viruses circulating in the US... Lois Collins with the Deseret News breaks down what you need to know about the viruses impacting Americans.

In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host for today's episode. Let's dive into a fascinating study published in JCO Precision Oncology entitled, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” This study led by Dr. Eric Michael Lander and colleagues examines a critical question: Can circulating tumor DNA help predict recurrence in patients with esophagogastric cancer who have achieved a favorable pathologic response after treatment? Esophagogastric cancer ranks as the seventh leading cause of cancer-related deaths worldwide. Despite aggressive treatment including neoadjuvant therapy followed by surgery, recurrence remains a grim reality for many patients. Interestingly, even those who achieve a pathologic complete response face a recurrence risk of up to 25%. This highlights a need for better tools to identify high-risk patients post-treatment. Circulating tumor DNA, or ctDNA for short, is emerging as a powerful biomarker in oncology. This minimally invasive blood-based test detects fragments of tumor DNA in the bloodstream, potentially signaling molecular residual disease before any radiographic evidence of recurrence appears. In this study, researchers focused on patients with locoregional esophagogastric cancer who had undergone neoadjuvant therapy followed by surgery, achieving either a complete or near complete pathologic response. Blood samples were collected postoperatively within a 16-week molecular residual disease window and during routine surveillance. The aim is to determine whether ctDNA positivity correlates with recurrence-free survival. The study analyzed 309 plasma samples from 42 patients across 11 institutions. Detectable ctDNA within the 16-week postoperative window was associated with a significantly higher recurrence risk. Among those with detectable ctDNA, 67% experienced recurrence compared to only 15% for those with undetectable ctDNA. This corresponds to a hazard ratio of 6.2, an alarming figure that underscores the potential for ctDNA as a prognostic tool. But the story doesn't end there. Postoperative surveillance ctDNA testing more than 16 weeks after surgery also proved to be a powerful prognostic indicator. Every patient with detectable ctDNA during surveillance eventually experienced recurrence, while only 7.4% of those with undetectable ctDNA relapse. These findings suggest that ctDNA testing could provide a critical lead time, enabling earlier interventions and personalized treatment strategies. Now let's talk about the clinical implications. Currently, patients who achieve a pathologic complete response often aren't considered for adjuvant therapies as the absence of visible disease is taken as a sign of remission. However, this study challenges that assumption. By integrating ctDNA testing into routine post-treatment surveillance, clinicians could identify high-risk patients who might benefit from additional therapy even when traditional imaging shows no signs of recurrence. This brings us to the bigger picture. Esophagogastric cancer treatment is evolving rapidly, with trials like CheckMate 577 and ESOPEC offering new insights into perioperative strategies. However, this study highlights a critical gap, the need for personalized, biomarker-driven approaches in the adjuvant setting. ctDNA could fill that gap, offering a non-invasive, dynamic way to monitor patients and guide clinical decisions. Of course, no study is without its limitations. The authors acknowledge the relatively small sample size and the retrospective nature of their analysis. They also note the variability in ctDNA testing and imaging schedules across institutions. However, the robust association between ctDNA positivity and recurrence-free survival makes a compelling case for further research in larger prospective cohorts. Looking ahead, what's the next step? The authors call for prospective validation of ctDNA as a prognostic tool, emphasizing its potential to refine risk stratification and optimize treatment strategies. Imagine a future where a simple blood test could dictate not only the need for additional therapies, but also the timing and type of intervention. As we wrap up, let's reflect on the broader impact of the study. By integrating ctDNA into routine cancer care, we could move closer to a world where treatments are not just effective, but also precisely tailored to each patient's unique biology and disease dynamics. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join our NEW Community Discord! https://www.discord.gg/podcast Today's topics we cover Epic's unforeseen job at handling cheaters. Topics: 1. Clix has his trio snake him in the final week! 2. Will the next LAN be in Raleigh or France? 3. Will Fortnite Competitive officially support the a new game mode? 4. Tune into the Comp awards! https://x.com/CompAwardsFN Follow Us On Twitter: MonsterDface - @MonsterDface Somebodysgun - @Somebodysgun LifeWithPanda - @LifewPanda  Email all of your complaints to us on twitter. Don't forget to leave us a comment!

This week on The Book Drop, we take a deeper look at the top circulating titles of 2024 for OPL, and discuss what they reveal about our community's awesome reading habits. This is The Book Drop.All the books and resources we talk about in this episode can be found at omahalibrary.org/podcast and here. Happening at the Library: Oregon Trail Live Action | Saturday, Jan. 18 | 1 to 3 p.m. | Saddlebrook Branch and Thursday, Jan. 23 | 6 to 7p.m. | Millard Branch Container Gardening Workshop | Tuesday, Jan. 21 | 10:30 to 11:30 a.m. | Swanson Branch Writer's Workshop | Tuesday, Jan. 21 | 5:30 to 7:30 p.m. | Benson Branch Explore all upcoming events at omahalibrary.org/events.

Circulating cell free DNA fragments are found in your bloodstream when cells die and release what's inside. Some of that DNA is your genetic material and some comes from mitochondria, the power plants of your cells. Johns Hopkins geriatrics expert … Are circulating DNA and inflammation related? Elizabeth Tracey reports Read More »

DNA fragments found in your blood, so called circulating cell free DNA, come from your cells as they die. Both genetic material and DNA from your energy plants, known as mitochondria, can be found, and both are implicated in increased … How does circulating DNA contribute to accelerated aging? Elizabeth Tracey reports Read More »

DNA fragments found circulating in an older person's blood are associated with frailty and Alzheimer's disease, studies by Peter Abadir, a geriatrics expert at Johns Hopkins, and colleagues have shown. These long term studies of several hundred older adults also … Higher levels of your own DNA circulating in your blood may be a problem, Elizabeth Tracey reports Read More »

See omnystudio.com/listener for privacy information.

Featuring an interview with Dr Seth Wander, including the following topics: ASCO Guidelines Rapid Recommendations Update for Testing for ESR1 Mutations (0:00) Real-world elacestrant use patterns and genomic biomarkers (4:43) Circulating tumor DNA (ctDNA) analyses with imlunestrant in the EMBER Phase I study (8:50) CME information and select publications

Liquid biopsies and circulating tumor DNA are changing and improving the way cancer is detected and treated. In this episode, Sameek Roychowdhury, PhD, MD, explains the basics of circulating tumor DNA, how it's being used at the James, his lab's clinical trials, and the promising future. “When a normal cell and a cancer die they sheds fragments of their DNA,” he said. “Cancer can be detected in the blood by looking for these fragments and this is becoming an important research tool and treatment tool for the care of cancer patients.” For example, about 50 percent of cancer patients who have a tumor surgically removed will have a recurrence. And it's very difficult to determine which patients will have the recurrence. Minimally invasive liquid biopsies after surgery “helps us stratify and determine patients with a lesser recurrence risk who won't need chemotherapy or immunotherapy treatment versus those patients who need even more treatment than we've normally given them in the past.” Monitoring circulating tumor DNA “also becomes part of the surveillance program and we'll do a precise test every three months that measures fragments in the blood,” Roychowdhury said, adding that finding a recurrence of cancer from these fragments, months before it would appear on more traditional scans “allows us to make a diagnosis about the molecular drivers of the cancer and we can begin treatment earlier and better understand which treatment options will work best.”

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Steve Reiter discuss various aspects of health optimization, focusing on longevity, pregnancy health, and breast cancer awareness. They explore innovative therapies like ozone treatment and detoxification methods, as well as provide actionable recommendations for couples planning for pregnancy. The conversation also addresses common myths surrounding breast cancer, emphasizing the importance of genetics and regular screenings. In this episode, the conversation delves into various aspects of cancer detection, treatment, and overall health maintenance. The discussion highlights the importance of understanding cancer testing methods, the reality of remission, and innovative therapies that support the immune system. Additionally, the episode emphasizes the significance of lung health through exercise and the critical role of dental hygiene in overall health. The conversation concludes with exciting developments in rejuvenation procedures that promise significant health benefits.   For the audience ·      Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·      The mitochondria play a crucial role in energy production and immune response. ·      Ozone therapy can rejuvenate mitochondrial function and aid in detoxification. ·      Frequent sexual activity can improve reproductive health for men. ·      Inositol can help women with PCOS improve their chances of pregnancy. ·      Adequate iodine levels can significantly impact a baby's IQ. ·      Regular exercise is beneficial for both pregnancy and overall health. ·      Avoiding heat exposure is important for male fertility. ·      Genetic testing can provide insights into breast cancer risk. ·      Mammograms are not the only screening method for breast cancer. ·      Circulating tumor cell tests can detect cancer earlier than traditional methods.  ·      Circulating tumor cells are crucial for cancer detection. ·      Remission does not mean the absence of cancer. ·      Innovative therapies can enhance immune response against cancer. ·      Exercise is vital for maintaining lung health. ·      Dental hygiene impacts systemic health significantly. ·      Root canals may lead to latent infections affecting health. ·      Regular exercise improves outcomes for cancer patients. ·      Breathing techniques can enhance lung function during exercise. ·      New rejuvenation procedures show promising results for recovery. ·      Understanding oral bacteria is essential for overall health.   Chapters   00:00 Introduction to Age Hacking and Longevity 10:01 Health Recommendations for Pregnancy: Answering a Listener's Q 21:44 Breast Cancer Awareness and Myths 26:09 Understanding Cancer Detection and Testing 28:50 The Reality of Cancer Remission 30:43 Innovative Cancer Therapies and Immune System Support 35:02 Enhancing Lung Health Through Exercise 43:00 The Importance of Dental Hygiene 48:43 Exciting Developments in Rejuvenation Procedures   Articles, News and Supplements mentioned Breast Cancer BREAST CANCER MYTHS https://www.wkrn.com/news/tennessee-news/breast-cancer-awareness-month-common-myths-about-the-disease/   BREAST CANCER GUIDE EVERYONE SHOULD HAVE https://www.telegraph.co.uk/health-fitness/conditions/cancer/breast-cancer/   NEW TECH FOR CANCER SCREENING https://www.cbsnews.com/chicago/news/doctor-talks-new-technology-importance-of-breast-cancer-screenings/   NEW WAY TO KILL CANCER CELLS https://medicalxpress.com/news/2024-10-cancer-cells-longer-people-breast.html   Healthy Lungs BENEFITS OF EXERCISE FOR PATIENTS WITH LUNG CANCER https://medicalxpress.com/news/2024-10-people-lung-cancer-grueling-evidence.html   HABITS PULMONOLOGISTS ARE BEGGING PEOPLE TO ADOPT AND DITCH https://parade.com/health/the-one-habit-to-adopt-asap-if-you-have-severe-asthma-according-to-pulmonologists   Dental Hygiene DENTAL HEALTH SENSING WITH SONIC TOOTHBRUSH https://medicalxpress.com/news/2024-10-exploring-dental-health-sonic-toothbrush.html   DENTAL HYGIENIST TALKS ABOUT HOW TO SPOT PERIODONTAL DISEASE https://www.buzzfeed.com/meganeliscomb/smell-your-used-floss-tiktok   UGLY YET MOST HIGHLY EFFECTIVE TOOTHBRUSH REVIEWERS HAVE EVER USED https://www.huffpost.com/entry/flossing-toothbrush_l_66fefb0de4b089d324aa50b1/amp   Supplements MOLECULAR HYDROGEN – ENERGY https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-30-ct   MOLECULAR HYDROGEN – CHILL https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-product-h2-chill   TOOTH AND GUM ESSENTIALS TOOTH PASTE https://gladdenlongevityshop.com/products/tooth-gum-essentials-toothpaste-4oz-1?_pos=1&_psq=dental&_ss=e&_v=1.0   TOOTH AND GUM TONICS https://gladdenlongevityshop.com/products/tooth-gum-tonic-18-fl-oz-1?_pos=2&_psq=dental&_ss=e&_v=1.0    UPGRADED IODINE https://gladdenlongevityshop.com/products/upgraded-memory-4fl-oz?pr_prod_strat=e5_desc&pr_rec_id=ec1b1eb28&pr_rec_pid=8125057761519&pr_ref_pid=8125058580719&pr_seq=uniform    ZINC https://gladdenlongevityshop.com/products/zinc-glycinate-120-gels-1?_pos=1&_psq=zinc&_ss=e&_v=1.0    Send your Qs for future episodes! Email: podcast@gladdenlongevity.com   Reach out to us at: Website: https://gladdenlongevity.com/  Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en  LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw 

A wild Beyonce conspiracy theory is taking hold, so we're going to explain it. P Diddy's scandals have had people asking who else might be involved, and a lot of attention has landed on Jay Z and Beyonce. Have a listen for all the juicy details...See omnystudio.com/listener for privacy information.

ReferencesChitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway.Clin Cancer Res 2008,14:6364-6370.Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene.Arch Physiol Biochem 2009, 115:58-71.Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.Int J Colorectal Dis 2006, 21:201-208.Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.J Natl Cancer Inst 2002, 94:972-980.Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.Novartis Found Symp 2004, 262:247-260; discussion 260-268.Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging.Science 1997, 278:419-424.Doi T, Shimada H, Makizako H, et al. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed.Neurobiol Aging 2015, 36:942-947.Calvo D, Gunstad J, Miller LA, et al. Higher serum insulin-like growth factor-1 is associated with better cognitive performance in persons with mild cognitive impairment.Psychogeriatrics 2013, 13:170-174.Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors.Endocr Rev 1994,15:80-101.Clemmons DR, Seek MM, Underwood LE. Supplemental essential amino acids augment the somatomedin-C/insulin-like growth factor I response to refeeding after fasting.Metabolism 1985, 34:391-395.Runchey SS, Pollak MN, Valsta LM, et al. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study.Eur J Clin Nutr 2012, 66:1146-1152.Brand-Miller JC, Liu V, Petocz P, Baxter RC. The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects.Am J Clin Nutr 2005, 82:350-354.Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer.Am J Clin Nutr 2005, 82:277-278.Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.J Clin Endocrinol Metab 2011, 96:2912-2920.Ranke MB, Osterziel KJ, Schweizer R, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays.Clin Chem Lab Med 2003, 41:1329-1334.Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.J Clin Endocrinol Metab 2014, 99:1712-1721.Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.Horm Res 2003, 60:53-60.Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition.Cancer Epidemiol Biomarkers Prev 2009,18:1333-1340.Fontana L, Klein S, Holloszy JO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk.Am J Clin Nutr 2006, 84:1456-1462.Fontana L, Weiss EP, Villareal DT, et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans.Aging Cell 2008, 7:681-687.Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations.J Clin Endocrinol Metab 2009, 94:1732-1739.Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men.J Clin Endocrinol Metab 2014, 99:E2308-2316.Svensson J, Carlzon D, Petzold M, et al. Both low and high serum IGF-I levels associate with cancer mortality in older men.J Clin Endocrinol Metab 2012, 97:4623-4630. .van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The Association of Serum Insulin-Like Growth Factor-I with Mortality, Cardiovascular Disease, and Cancer in the Elderly: A Population-Based Study.J Clin Endocrinol Metab 2010.Arai Y, Takayama M, Gondo Y, et al. Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age.J Gerontol A Biol Sci Med Sci 2008, 63:1209-1218.Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke.J Clin Endocrinol Metab 2005, 90:5937-5941.Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.Lancet 1998, 351:1393-1396.Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.Science 1998, 279:563-566.